EF Hutton Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Enlivex Therapeutics (NASDAQ:ENLV) and maintained a price target of $13.
September 26, 2024 | 6:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton's analyst Jason Kolbert has reiterated a Buy rating for Enlivex Therapeutics, maintaining a price target of $13. This suggests confidence in the company's future performance.
The reaffirmation of a Buy rating and a $13 price target by EF Hutton indicates a positive outlook on Enlivex Therapeutics' future performance. This can lead to increased investor confidence and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100